1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Rahbari NN, Mehrabi A, Mollberg NM, et al:
Hepatocellular carcinoma: current management and perspectives for
the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kobayashi A, Kawasaki S, Miyagawa S, et
al: Results of 404 hepatic resections including 80 repeat
hepatectomies for hepatocellular carcinoma. Hepatogastroenterology.
53:736–741. 2006.PubMed/NCBI
|
4
|
Chen MS, Li JQ, Zheng Y, et al: A
prospective randomized trial comparing percutaneous local ablative
therapy and partial hepatectomy for small hepatocellular carcinoma.
Ann Surg. 243:321–328. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Taura K, Ikai I, Hatano E, Fujii H, Uyama
N and Shimahara Y: Implication of frequent local ablation therapy
for intrahepatic recurrence in prolonged survival of patients with
hepatocellular carcinoma undergoing hepatic resection: an analysis
of 610 patients over 16 years old. Ann Surg. 244:265–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Chen PJ, Chen DS, Lai MY, et al: Clonal
origin of recurrent hepatocellular carcinomas. Gastroenterology.
96:527–529. 1989.PubMed/NCBI
|
7
|
Imamura H, Matsuyama Y, Tanaka E, et al:
Risk factors contributing to early and late phase intrahepatic
recurrence of hepatocellular carcinoma after hepatectomy. J
Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
8
|
Portolani N, Coniglio A, Ghidoni S, et al:
Early and late recurrence after liver resection for hepatocellular
carcinoma: prognostic and therapeutic implications. Ann Surg.
243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Cucchetti A, Piscaglia F, Caturelli E, et
al: Comparison of recurrence of hepatocellular carcinoma after
resection in patients with cirrhosis to its occurrence in a
surveilled cirrhotic population. Ann Surg Oncol. 16:413–422. 2009.
View Article : Google Scholar
|
10
|
Matsuda M, Fujii H, Kono H and Matsumoto
Y: Surgical treatment of recurrent hepatocellular carcinoma based
on the mode of recurrence: repeat hepatic resection or ablation are
good choices for patients with recurrent multicentric cancer. J
Hepatobiliary Pancreat Surg. 8:353–359. 2001. View Article : Google Scholar : PubMed/NCBI
|
11
|
Morimoto O, Nagano H, Sakon M, et al:
Diagnosis of intrahepatic metastasis and multicentric
carcinogenesis by microsatellite loss of heterozygosity in patients
with multiple and recurrent hepatocellular carcinomas. J Hepatol.
39:215–221. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nakata T, Seki N, Miwa S, et al:
Identification of genes associated with multiple nodules in
hepatocellular carcinoma using cDNA microarray: multicentric
occurrence or intrahepatic metastasis? Hepatogastroenterology.
55:865–872. 2008.PubMed/NCBI
|
13
|
Nomoto S, Yamashita K, Koshikawa K, Nakao
A and Sidransky D: Mitochondrial D-loop mutations as clonal markers
in multicentric hepatocellular carcinoma and plasma. Clin Cancer
Res. 8:481–487. 2002.PubMed/NCBI
|
14
|
Nomoto S, Kinoshita T, Kato K, et al:
Hypermethylation of multiple genes as clonal markers in
multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265.
2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Stangegaard M: Gene expression analysis
using agilent DNA microarrays. Methods Mol Biol. 529:133–145. 2009.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Bibikova M and Fan JB: GoldenGate assay
for DNA methylation profiling. Methods Mol Biol. 507:149–163. 2009.
View Article : Google Scholar
|
17
|
Okamura Y, Nomoto S, Hayashi M, et al:
Identification of the bleomycin hydrolase gene as a methylated
tumor suppressor gene in hepatocellular carcinoma using a novel
triple-combination array method. Cancer Lett. 312:150–157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Takai D and Jones PA: The CpG island
searcher: a new WWW resource. In Silico Biol. 3:235–240.
2003.PubMed/NCBI
|
19
|
Wang Z, Zhang G, Wu J and Jia M: Adjuvant
therapy for hepatocellular carcinoma: current situation and
prospect. Drug Discov Ther. 7:137–143. 2013.PubMed/NCBI
|
20
|
Takenaka K, Adachi E, Nishizaki T, et al:
Possible multicentric occurrence of hepatocellular carcinoma: a
clinicopathological study. Hepatology. 19:889–894. 1994. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kumada T, Nakano S, Takeda I, et al:
Patterns of recurrence after initial treatment in patients with
small hepatocellular carcinoma. Hepatology. 25:87–92. 1997.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Amato D and Wang C: Resolution of
thrombocytopenia with JAK2 mutation in a patient with Gaucher
disease. Blood. 122:4287–4288. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Kralovics R, Passamonti F, Buser AS, et
al: A gain-of-function mutation of JAK2 in myeloproliferative
disorders. N Engl J Med. 352:1779–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hellgren G, Jansson JO, Carlsson LM and
Carlsson B: The growth hormone receptor associates with Jak1, Jak2
and Tyk2 in human liver. Growth Horm IGF Res. 9:212–218. 1999.
View Article : Google Scholar : PubMed/NCBI
|
25
|
GeneCards. Weizmann Institute of Science.
2014, Available from http://www.genecards.org.
|
26
|
Calvisi DF, Ladu S, Gorden A, et al:
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Cressman DE, Diamond RH and Taub R: Rapid
activation of the Stat3 transcription complex in liver
regeneration. Hepatology. 21:1443–1449. 1995. View Article : Google Scholar : PubMed/NCBI
|
28
|
Trautwein C, Rakemann T, Niehof M,
Rose-John S and Manns MP: Acute-phase response factor, increased
binding, and target gene transcription during liver regeneration.
Gastroenterology. 110:1854–1862. 1996. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ono M, Chia DJ, Merino-Martinez R,
Flores-Morales A, Unterman TG and Rotwein P: Signal transducer and
activator of transcription (Stat) 5b-mediated inhibition of
insulin-like growth factor binding protein-1 gene transcription: a
mechanism for repression of gene expression by growth hormone. Mol
Endocrinol. 21:1443–1457. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yeh YT, Lee KT, Tsai CJ, Chen YJ and Wang
SN: Prolactin promotes hepatocellular carcinoma through Janus
kinase 2. World J Surg. 36:1128–1135. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yoshikawa H, Matsubara K, Qian GS, et al:
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced
by methylation in human hepatocellular carcinoma and shows
growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI
|